Patent intelligence · US
US 10426817
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
Patent details — US 10426817
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 1, 2019
- Expiration
- Sep 26, 2039
- Applicant
- MacRegen, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K38/1709, A61K45/06, A61K9/0048
Quick answer
US 10426817 (Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics) is held by MacRegen, Inc.. Status: granted. Granted Oct 1, 2019. Expires Sep 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MacRegen, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K38/1709, A61K45/06, A61K9/0048
More from MacRegen, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10426817?
US 10426817 (Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics) is held by MacRegen, Inc.. Status: granted. Granted Oct 1, 2019. Expires Sep 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10426817?
MacRegen, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10426817 expire?
Our index shows an expiration date of Sep 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.